Sen Wu

Dr. Sen Wu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
WYWenjian Yao
Wenjian Yao
LSLinlin Shang
Linlin Shang
YWYinghao Wang
Yinghao Wang
LXLei Xu
Lei Xu
YBYu Bai
Yu Bai
SWSen Wu
Sen Wu
The RAR-related orphan receptor alpha (RORA), a circadian clock molecule, is highly associated with anti-oncogenes. In this paper, we defined the precise action and mechanistic basis of RORA in ESCC development under hypoxia. Expression analysis was conducted by RT-qPCR, western blotting, immunofluorescence (IF), and immunohistochemistry (IHC) assays. The functions of RORA were assessed by detecting its regulatory effects on cell viability, motility, invasion, and tumor growth. DNA pull-down assay and proteomic analysis were employed to identify proteins bound to the RORA promoter. The promoter methylation level of RORA was detected by DNA pyrosequencing. RNA-seq analysis was performed to explore the downstream mechanisms of RORA, and the transcriptional regulation of RORA on SLC2A3 was verified by ChIP-qPCR and dual-luciferase reporter assay. Glycolysis was assessed by detecting the consumption of glucose and the production of lactic acid and ATP. In vitro, RORA was shown to suppress ESCC cell viability, motility, and invasion under hypoxic condition. In vivo, increased RORA expression in mouse xenografts impeded tumor growth. DNMT1 was identified to widely exist in the RORA promoter, increasing DNA methylation and reducing RORA expression in hypoxia-induced KYSE150 ESCC cells. Mechanistically, RORA was found to inactivate the transcription of glucose transporter protein SLC2A3 by interacting with its promoter F1 region. Furthermore, rescue experiments revealed that RORA-mediated suppressive effects on ESCC cell migration and invasion were largely based on its negative regulation of SLC2A3 and glycolysis. DNMT1-driven methylation of RORA promotes ESCC progression largely through affecting SLC2A3 transcription and glycolysis. These findings turn RORA into potential target of anti-cancer therapeutic agents. RORA works as a tumor suppressor in ESCC under hypoxia. DNMT1 downregulates RORA by induction of methylation. RORA inactivates SLC2A3 transcription through its promoter F1 region. RORA inactivates SLC2A3 transcription to inhibit ESCC cell glycolysis and metastasis.

8 November 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
WYWenjian Yao
Wenjian Yao
JWJianjun Wang
Jianjun Wang
LZLi Zhu
Li Zhu
XJXiangbo Jia
Xiangbo Jia
LXLei Xu
Lei Xu
LWLi Wei
Li Wei
Background: Increasing researches have been reported that epigenetic alterations play critical roles in ESCC development. However, the role of the histone demethylase KDM4D in ESCC tumorigenesis is poorly investigated. This study aims to discover the underlying mechanisms between KDM4D and ESCC progression.Methods: CCK-8 assays, clone formation assay and soft-agar assays were performed to assess cell proliferation. Transwell assay was utilized to assess cell migration efficiency, while sphere formation assay was used to evaluate the cell self-renewal ability. Bioinformatic analysis was conducted to identify prognostic factors and predict the potential E3 ubiquitin ligases. In vitro ubiquitination assay was conducted to confirm the regulations between SYVN1 and HMGB1. The mRNA levels or protein levels of genes were detected by real-time PCR and western blot analysis. In vivo tumor xenograft models were used to determine whether the HMGB1 inhibition affected the malignant features of ESCC cells.Result: Epigenome screening and low-throughput validations highlighted that KDM4D is a tumor suppressor in ESCC. KDM4D expressed lowly in tumors that predicts poor prognosis. KDM4D deficiency significantly enhanced tumor growth, migration and stemness. Mechanistically, KDM4D transcriptionally activates SYVN1 expressions via H3K9me3 demethylation at the promoter region, thereby triggering the ubiquitin-dependent degradation of HMGB1. Low KDM4D depended on accumulated HMGB1 to drive ESCC progression and aggressiveness. Targeting HMGB1 (Glycyrrhizin) could remarkably suppress ESCC tumor growth in vitro and in vivo, especially in KDM4D-deficient cells.Conclusions: We systematically identified KDM4D/SYVN1/HMGB1 axis in ESCC progression, proving novel biomarkers and potential therapeutic targets.

31 October 2023 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
WYWenjian Yao
Wenjian Yao
XCXiaohai Cui
Xiaohai Cui
HPHaodong Peng
Haodong Peng
YZYongkang Zhang
Yongkang Zhang
XJXiangbo Jia
Xiangbo Jia
JZJian Zhao
Jian Zhao
Esophageal carcinoma (EC), one of the most lethal human malignancies, lacks effective targeted therapies. Indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in a variety of cancers, but its role and mechanism in EC are still unclear. Immunohistochemistry and qRT-PCR were used to analyze the expression of IDO1 in EC, and the prognostic value of IDO1 in EC was evaluated by Kaplan-Meier test. The in vitro and in vivo function loss/acquisition tests were performed to evaluate the biological effects of IDO1 in EC. The mechanism of action of IDO1-regulation EC was explored through Firefly luciferase & Renilla luciferase activity reporter, chromatin immunoprecipitation (ChIP) and immunofluorescence (IF) assays. Clinically, IDO1 expression was abnormally elevated in EC and positively correlated with overall survival. Functionally, IDO1 was contributed to the proliferation and migration of EC cells. Mechanically, IDO1 regulated the expression of chemokine C-X-C ligand 10 (CXCL10) by promoting the entry of NF-κB into the nucleus to combine with the promoter of CXCL10. Consistently, IDO1 facilitated EC progression may dependent on the presence of CXCL10. Moreover, NF-κB alleviated the inhibitory effect of IDO1 knockdown on EC. IDO1 drove the progression of EC by directly binding NF-κB and CXCL10, the finding that may provide an effective theoretical basis for precise therapies for EC.

10 July 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
WYWenjian Yao
Wenjian Yao
JLJian Liu
Jian Liu
ZHZhaoyao Hou
Zhaoyao Hou
XJXiangbo Jia
Xiangbo Jia
DYDong Yang
Dong Yang
LWLi Wei
Li Wei

23 February 2025 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
XZXinhua Zhang
Xinhua Zhang
YBYu Bai
Yu Bai
LSLinlin Shang
Linlin Shang
YWYinghao Wang
Yinghao Wang
WYWenjian Yao
Wenjian Yao
SWSen Wu
Sen Wu